Mylan Gross Profit 2006-2018 | MYL

Current and historical gross profit for Mylan (MYL) from 2006 to 2018. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services. Mylan gross profit for the twelve months ending June 30, 2018 was $4.419B. Mylan gross profit for the three months ending June 30, 2018 was $0.963B, representing a 21.45% decline from the same quarter last year.
Mylan Annual Gross Profit
(Millions of US $)
2017 $4,783
2016 $4,697
2015 $4,216
2014 $3,528
2013 $3,040
2012 $2,908
2011 $2,563
2010 $2,217
2009 $2,074
2008 $2,070
2007 $874
2007 $844
2006 $628
2005 $624
Mylan Quarterly Gross Profit
(Millions of US $)
Q2 2018 $963
Q1 2018 $984
Q4 2017 $1,295
Q3 2017 $1,178
Q2 2017 $1,225
Q1 2017 $1,085
Q4 2016 $1,335
Q3 2016 $1,283
Q2 2016 $1,172
Q1 2016 $907
Q4 2015 $1,063
Q3 2015 $1,315
Q2 2015 $1,008
Q1 2015 $830
Q4 2014 $969
Q3 2014 $1,012
Q2 2014 $809
Q1 2014 $738
Q4 2013 $796
Q3 2013 $809
Q2 2013 $742
Q1 2013 $694
Q4 2012 $742
Q3 2012 $793
Q2 2012 $703
Q1 2012 $670
Q4 2011 $645
Q3 2011 $658
Q2 2011 $669
Q1 2011 $591
Q4 2010 $579
Q3 2010 $580
Q2 2010 $542
Q1 2010 $516
Q4 2009 $516
Q3 2009 $505
Q2 2009 $528
Q1 2009 $526
Q4 2008 $395
Q3 2008 $911
Q2 2008 $414
Q1 2008 $350
Q4 2007 $121
Q3 2007 $222
Q2 2007 $297
Q1 2007 $235
Q4 2006 $225
Q3 2006 $196
Q2 2006 $188
Q1 2006 $0
Q4 2005 $156
Q3 2005 $143
Q2 2005 $168
Q1 2005 $0
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $19.354B $11.908B
Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as Mylan Inc., is based in Canonsburg, Pennsylvania.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $62.549B 10.73
Teva Pharmaceutical Industries (TEVA) Israel $22.320B 6.24
Bausch Health Cos (BHC) Canada $7.455B 5.57
Dr Reddy's Laboratories (RDY) India $5.335B 23.83
Mallinckrodt Public Limited Company (MNK) United Kingdom $2.637B 4.48
Akorn (AKRX) United States $2.348B 11.63
Supernus Pharmaceuticals (SUPN) United States $2.271B 24.30
Assembly Biosciences (ASMB) United States $1.006B 0.00
Amphastar Pharmaceuticals (AMPH) United States $0.816B 117.53
CymaBay Therapeutics (CBAY) United States $0.718B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.637B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.613B 0.00
Homology Medicines (FIXX) United States $0.587B 0.00
Voyager Therapeutics (VYGR) United States $0.574B 0.00
Corium (CORI) United States $0.336B 0.00
Teligent (TLGT) United States $0.223B 0.00
Sol-Gel Technologies (SLGL) Israel $0.119B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.116B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.077B 0.00
Versartis (VSAR) United States $0.060B 0.00
Aevi Genomic Medicine (GNMX) United States $0.058B 0.00
Evoke Pharma (EVOK) United States $0.040B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.022B 0.00
Acasti Pharma (ACST) Canada $0.017B 0.00
China Pharma Holdings (CPHI) China $0.010B 0.00
Agile Therapeutics (AGRX) United States $0.009B 0.00